Posted on 12 February 2015
Actavis has entered into an agreement with Mayne Pharma, under which it will divest the U.S. rights to the Doryx brand acne treatment and related assets to Mayne for approximately $50 million.
The transaction is expected to close prior to the end of February.
|Searching for more deal information? Current Partnering offers the following options:|
- CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
- Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
- CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time
Under the terms of the agreement, Actavis will continue to package, distribute and actively promote the product for a transition period until May 2 following the close of the transaction.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2015
View: Top pharmaceutical companies
View: Top biotech companies
Reports: Browse our extensive deal making report portfolio